Combination Products in Clinical Practice: Canadian Experience

Abstract

Purpose.

Data are provided from the Combigan Early Experience Data (CEED) study, which evaluated patients’ clinical experience of using Combigan^® in a real-life setting.

Methods.

CEED was a Canadian open-label, prospective 2-month surveillance trial involving 47 investigators and 453 patients. Primary outcomes were intraocular pressure (IOP) reduction and patient satisfaction. Adverse events and doctor satisfaction were secondary outcomes. Most patients were aged over 50, with 82% white, and nearly 90% had open-angle glaucoma. Combigan was used either as a replacement of, or an addition to, the patients’ existing therapy.

Results.

Switching to, or adding, Combigan to existing glaucoma therapy led to an additional reduction in IOP of 3.8 mmHg, and 70% of patients achieved IOP ≤18. mmHg compared with 31% at baseline. There was an additional reduction in IOP of almost 3 mmHg in patients switched from Cosopt to Combigan and the proportion of eyes achieving an IOP ≤18 mmHg more than doubled in these patients. Altogether, 92% of patients who switched from Cosopt alone to Combigan alone rated Combigan as more comfortable; 98% of doctors rated Combigan as good or excellent compared with other IOP-lowering medications.

Conclusions.

Combigan effectively lowered IOP over the 2-month trial, and the findings suggest that it is as effective as, or more effective than, Cosopt.